Fig 1.
Schematic diagrams of a hybrid model consisted of a decision tree model along with a Markov model.
Table 1.
Base-case analysis findings.
Table 2.
Fully incremental analysis findings.
Table 3.
Scenario analysis results.
Fig 2.
Cost-effectiveness acceptability curve.
Sequence 1 was secukinumab followed by ixekizumab or brodalumab and guselkumab. Sequence 2 was ixekizumab followed by secukinumab or brodalumab and guselkumab. Sequence 3 was brodalumab followed by secukizumab or ixekizumab and guselkumab.